Proteostasis Therapeutics, Inc. (PTI) Stake Maintained by Hillhouse Capital Management Ltd.
Hillhouse Capital Management Ltd. maintained its stake in shares of Proteostasis Therapeutics, Inc. (NASDAQ:PTI) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 865,923 shares of the company’s stock at the close of the 2nd quarter. Hillhouse Capital Management Ltd. owned approximately 3.45% of Proteostasis Therapeutics worth $4,053,000 at the end of the most recent quarter.
Several other hedge funds also recently modified their holdings of the company. Goldman Sachs Group Inc. increased its stake in shares of Proteostasis Therapeutics by 364.3% in the second quarter. Goldman Sachs Group Inc. now owns 51,911 shares of the company’s stock valued at $243,000 after buying an additional 40,731 shares during the period. Bain Capital Public Equity Management LLC acquired a new stake in shares of Proteostasis Therapeutics in the second quarter valued at about $1,233,000. Dimensional Fund Advisors LP acquired a new stake in shares of Proteostasis Therapeutics in the second quarter valued at about $296,000. FMR LLC increased its stake in shares of Proteostasis Therapeutics by 2.3% in the second quarter. FMR LLC now owns 2,944,915 shares of the company’s stock valued at $13,782,000 after buying an additional 66,111 shares during the period. Finally, Jennison Associates LLC increased its stake in shares of Proteostasis Therapeutics by 6.2% in the second quarter. Jennison Associates LLC now owns 2,075,439 shares of the company’s stock valued at $9,713,000 after buying an additional 120,575 shares during the period. 73.71% of the stock is owned by institutional investors.
Shares of Proteostasis Therapeutics, Inc. (NASDAQ PTI) traded down 0.95% during midday trading on Thursday, hitting $2.09. The stock had a trading volume of 15,000 shares. Proteostasis Therapeutics, Inc. has a 1-year low of $1.71 and a 1-year high of $16.67. The firm’s 50-day moving average price is $2.03 and its 200-day moving average price is $4.36. The stock’s market cap is $52.46 million.
Several brokerages have recently weighed in on PTI. Zacks Investment Research cut Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Proteostasis Therapeutics in a research note on Friday, June 30th. Finally, Leerink Swann reissued an “outperform” rating and issued a $9.00 price target (down previously from $17.00) on shares of Proteostasis Therapeutics in a research note on Wednesday, August 16th.
Proteostasis Therapeutics Profile
Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.
Want to see what other hedge funds are holding PTI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Proteostasis Therapeutics, Inc. (NASDAQ:PTI).
Receive News & Ratings for Proteostasis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.